Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Quantification of Human VPS33B expression in mouse liver via lentiviral transfection

ABSTRACT: Arthrogryposis, Renal dysfunction and Cholestasis (ARC) syndrome is a lethal autosomal recessive disorder caused by deficiencies of VPS33B or VIPAS39 trafficking proteins. VPS33B deficiency in hepatocytes disrupts bile secretion, leading to progressive liver fibrosis, terminal liver disease and death of most ARC patients before the age of one year. Here, we developed a lentiviral gene therapy for ARC syndrome. Therapeutic vectors EF1-VPS (ubiquitous), LP1-VPS (liver-specific) and GFP controls were produced and tested in vitro in HepG2 VPS33B-/- cells. In vivo safety was assessed using neonatal heterozygous Vps33bLiver+/- mice. For efficacy experiments, Vps33bLiver-/- mice received neonatal intravenous injections combined with transient liver macrophage depletion and cholestasis was exacerbated using a 0.25% cholic acid diet. EF1-VPS and EF1-GFP vectors raised safety concerns, with 3 in 10 treated mice developing hepatocellular carcinomas, compared to none treated with the liver-specific vectors. Integration site analysis evidenced clonal expansion and Tox as a common vector integration locus in the 3 carcinomas. The safe LP1-VPS vector showed efficacy through significant improvement in survival, growth, and ARC-specific biomarkers. Microscopy liver analysis displayed reduced fibrosis and restoration of bile canalicular ultrastructure. These findings offer hope for ARC syndrome patients and serve as proof-of-concept for lentiviral gene therapy safety and efficacy studies in early-onset liver disorders.[

ORGANISM(S): Homo Sapiens

SUBMITTER: Wendy Heywood

PROVIDER: PXD077802 | panorama | Wed Apr 29 00:00:00 BST 2026

REPOSITORIES: PanoramaPublic

ACCESS DATA

Json Xml

Similar Datasets

Safety and efficacy analysis of in vivo lentiviral gene therapy in pre-clinical ARC syndrome models

Project description:Arthrogryposis, Renal dysfunction and Cholestasis (ARC) syndrome is a rare inherited disorder caused by defects in the VPS33B trafficking protein, leading to impaired bile flow, progressive liver disease and early death. No effective treatments are currently available. Gene therapy offers a potential approach by restoring the missing VPS33B protein in liver cells. Here, we show that liver-targeted lentiviral gene therapy safely and effectively rescues key features of ARC syndrome in a mouse model following in vivo administration by intravenous injection, combined with transient liver macrophage depletion. To assess the treatment efficacy, disease severity is exacerbated by 0.25% cholic acid diet feeds. A liver-specific vector shows a favourable safety profile over a ubiquitous vector. Mice receiving the safe liver-specific vector display improved survival, growth and liver function, reduced fibrosis and bile canaliculi restoration. These findings support targeted gene therapy as a promising treatment for ARC syndrome and related early-onset liver diseases.

2026-05-06 | GSE329589 | GEO

Safety and efficacy analysis of in vivo lentiviral gene therapy in pre-clinical ARC syndrome models

Project description:Safety and efficacy analysis of in vivo lentiviral gene therapy in pre-clinical ARC syndrome models

2026-04-29 | MTBLS14408 | MetaboLights

Tweaking lentiviral vector design balances efficacy and safety in liver-directed gene therapy for familial hypercholesterolemia

Project description:Elevated low-density lipoprotein (LDL) cholesterol is the hallmark of familial hypercholesterolemia (FH), an inherited disease mostly due to mutations in the LDL receptor (LDLR)-encoding gene. Here we enforced overexpression of LDLR in hepatocytes by in vivo lentiviral vector (LV) gene therapy and normalized circulating LDL cholesterol in a mouse model of FH. One year after gene therapy we detected a high incidence of hepatic tumors in treated mice. Analysis of LV genomic integration sites in the liver tumors revealed expanded clones bearing LV insertions within the Fyn-related kinase (Frk) gene, a known hepatic oncogene, inducing the formation of aberrant LDLR-FRK transcripts. When we purposely overexpressed LDLR-FRK by LV gene transfer, we observed hepatocellular hyperplasia and hypertrophy, supporting a role of this chimeric protein in oncogenesis. Since high expression of this chimeric oncogene and the LDLR likely cooperated to cause liver toxicity, we reduced the strength of LDLR expression within LV. We achieved normalization of circulating LDL cholesterol in two FH mouse models and prevention of atherosclerosis, even under high-fat diet challenge, without any long-term liver tumorigenicity. Overall, our in-depth assessment of the efficacy and safety of in vivo gene therapy for FH provides new insights into mechanisms of action and potential vulnerabilities, with implications for future developments of lipid-lowering gene therapies.

2026-04-15 | GSE315905 | GEO

Genotoxicity after adeno-associated virus (AAV) gene therapy is dependent upon dose, treatment age and enhancer-promoter selection

Project description:AAV gene therapy has recently been approved for clinical use and shown to be efficacious and safe in a growing number of clinical trials. However, the safety of AAV as a gene therapy has been challenged by a few studies that documented hepatocellular carcinoma (HCC) after AAV gene delivery in mice. The association between AAV and HCC has been difficult to reconcile and is the subject of intense debate because numerous AAV studies have not reported toxicity. Here, we report a comprehensive study of HCC in a large number of mice following therapeutic AAV gene delivery. Using a sensitive high-throughput integration site-capture technique and global expressional analysis, we found that AAV integration into the Rian locus and the over-expression of a proximal gene, Rtl1, were associated with HCC. In addition, we identify a number of genes with differential expression that maybe useful in the study, diagnosis and treatment of HCC. We demonstrate that AAV vector dose, enhancer-promoter selection, and the timing of gene delivery are the defining factors in AAV-mediated insertional mutagenesis. Our results help explain the AAV-mediated genotoxicity previously observed and have important implications for the design of both safer AAV vectors and gene therapy studies. To investigate the possibility that insertional mutagenesis by AAV contributed to the development of HCC, we collected normal and tumor tissues from adult mouse livers that received AAV injection at a neonatal stage.

2015-01-01 | E-GEOD-57597 | biostudies-arrayexpress

Genotoxicity after adeno-associated virus (AAV) gene therapy is dependent upon dose, treatment age and enhancer-promoter selection (microRNA)

2015-09-01 | E-GEOD-61632 | biostudies-arrayexpress

Identifying biomarkers of heterogeneity and transplantation efficacy in retinal pigment epithelial cells

Project description:Transplantation of retinal pigment epithelial (RPE) cells holds great promise for patients with retinal degenerative diseases, such as age-related macular degeneration. In-depth characterization of RPE cell product identity and critical quality attributes are needed to enhance efficacy and safety of replacement therapy strategies. Here, we characterized an adult RPE stem cell-derived (RPESC-RPE) cell product using bulk and single-cell RNA sequencing (scRNA-seq), assessing functional cell integration in vitro into a mature RPE monolayer and in vivo efficacy by vision rescue in the Royal College of Surgeons rats. scRNA-seq revealed several distinct subpopulations in the RPESC-RPE product, some with progenitor markers. We identified RPE clusters expressing genes associated with in vivo efficacy and increased cell integration capability. Gene expression analysis revealed lncRNA (TREX) as a predictive marker of in vivo efficacy. TREX knockdown decreased cell integration while overexpression increased integration in vitro and improved vision rescue in the RCS rats.

2023-08-14 | GSE211189 | GEO

Identifying Biomarkers of Heterogeneity and Transplantation Efficacy in Retinal Pigment Epithelial Cells [scRNA-seq]

Project description:Transplantation of retinal pigment epithelial (RPE) cells holds great promise for patients with retinal degenerative diseases such as age-related macular degeneration. In-depth characterization of RPE cell product identity and critical quality attributes are needed to enhance efficacy and safety of replacement therapy strategies. Here we characterized an adult RPE stem cell-derived (RPESC-RPE) cell product using bulk and single cell RNA sequencing (sc-RNA-seq), assessing functional cell integration in vitro into a mature RPE monolayer and in vivo efficacy by vision rescue in the Royal College of Surgeons rats. scRNA-seq revealed several distinct subpopulations in the RPESC-RPE product, some with progenitor markers. We identified RPE clusters expressing genes associated with in vivo efficacy and increased cell integration capability. Gene expression analysis revealed a lncRNA (TREX) as a predictive marker of in vivo efficacy. TREX knockdown decreased cell integration while overexpression increased integration in vitro and improved vision rescue in the RCS rats.

2023-08-14 | GSE211188 | GEO

Identifying Biomarkers of Heterogeneity and Transplantation Efficacy in Retinal Pigment Epithelial Cells [Bulk RNA-seq]

2023-08-14 | GSE211187 | GEO

Project description:Safety and efficacy analysis of in vivo lentiviral gene therapy in pre-clinical ARC syndrome models

| PRJNA1458313 | ENA

Identification of genes and molecular pathways associated with anti-miR-182 treatment.

Project description:To identify genes differentially modulated by anti-miR-182 treatment in a liver melanoma metastasis mouse model. Targeting oncogenic microRNAs is emerging as a promising strategy for cancer therapy. Here we provide proof-of-principle for the safety and efficacy of miRNA targeting against metastatic tumors. We tested the effect of targeting miR-182, a pro-metastatic miRNA frequently overexpressed in melanoma, whose silencing represses invasion and induces apoptosis in vitro. In particular, we assessed the effect of anti-miR-182 oligonucleotides synthesized with 2â sugar modifications and a phosphorothioate backbone in a mouse model of melanoma liver metastasis. Luciferase imaging showed that mice treated with anti-miR-182 had an appreciably lower burden of liver metastases compared to the control. We confirmed that miR-182 levels were effectively downregulated in the anti-miR treated tumors relative to the scrambled treated tumor both in the liver and in the spleen. This downregulation was accompanied by an upregulation of miR-182 direct targets. Transcriptome analysis of mouse tissues treated with anti-miR-182 or scramble oligonucleotides revealed an enrichment for genes controlling survival, adhesion and migration modulated in response to anti-miR-182 treatment. These data indicate that in vivo administration of anti-miRs allows for efficient miRNA targeting and concomitant upregulation of target levels. Our results suggest that the use of anti-miR-182 is a promising therapeutic strategy for metastatic melanoma and provide solid proof-of-principle for similar strategies against other metastatic tumors. Keywords: Differentially expressed genes (mRNAs) in response to miRNA inhibition Quadruplicate (n=4) samples of anti-miR-182 treated human melanoma metastasis compared to quadruplicate control treated metastasis.

2010-10-21 | E-GEOD-24824 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data